Back to Search Results
Study Complete
Sponsor ID
20190320

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Sponsor ID
20190320
Clinicaltrials.gov ID
NCT05581992
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The primary objective of this study is to evaluate the PK profile of AMG 510 alone and in combination with omeprazole in healthy participants.

Additional Study Details

Phase
Phase 1
Product
AMG 510
Type
Interventional
Masking
None (Open Label)
Enrollment
14
Additional Study Details

Protocol Summary

Primary Outcome Measures

Maximum Observed Plasma Concentration (Cmax) of AMG 510

Timeframe: Day 1 and Day 9

Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 510

Timeframe: Day 1 and Day 9

AUC from time Zero to Infinity (AUCinf) of AMG 510

Timeframe: Day 1 and Day 9

Secondary Outcome Measures

Number of Participants with an Adverse Event (AE)

Timeframe: Day 1 to Day 11

Study Documents

Study Synopsis
Available Language(s): English
Download Document(s)

Locations

Location
Status
Contact Us
Location
Covance Clinical Research Unit, Inc
Daytona Beach, FL, United States, 32117
Status
Completed
Study Info
Age
18 - 60 Years
Condition
  • Healthy Subjects
    • Sex
    All
    Trial Dates
    Jan 2020 - Jan 2020
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Healthy male subjects or female participants, between 18 and 60 years of age (inclusive), at the time of Screening. - Body mass index, between 18 and 30 kg/m2 (inclusive), at the time of Screening. - Females of nonchildbearing potential.
    Exclusion Criteria:
    - Inability to swallow oral medication or history of malabsorption syndrome. - History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor. - Poor peripheral venous access. - History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.